Evaxion A/S 6-K Filing

From the Filing

0001171843-25-007403.txt : 20251118 0001171843-25-007403.hdr.sgml : 20251118 20251118110010 ACCESSION NUMBER: 0001171843-25-007403 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 5 CONFORMED PERIOD OF REPORT: 20251118 FILED AS OF DATE: 20251118 DATE AS OF CHANGE: 20251118 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Evaxion A/S CENTRAL INDEX KEY: 0001828253 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: G7 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39950 FILM NUMBER: 251493252 BUSINESS ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: DR NEERGAARDS VEJ 5F CITY: HOERSHOLM PROVINCE COUNTRY: G7 BUSINESS PHONE: 4552656554 MAIL ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: DR NEERGAARDS VEJ 5F CITY: HOERSHOLM PROVINCE COUNTRY: G7 FORMER COMPANY: FORMER CONFORMED NAME: Evaxion Biotech A/S DATE OF NAME CHANGE: 20201014 6-K 1 f6k_111825.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2025 Commission File Number: 001-39950 Evaxion A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐ INCORPORATION BY REFERENCE This report on Form 6-K shall be deemed to be incorporated by reference in Evaxion A/S’s registration statements on Form S-8 (File No. 333-255064), on Form F-3 (File No. 333-265132), on Form F-1, as amended (File No. 333-266050), Form F-1 (File No. 333-276505), Form F-1 (File No. 333-279153), Form F-1 (File No. 333-283304), and Form F-3 (File No. 333- 285778), including any prospectuses forming a part of such registration statements and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. Amendment to Articles of Association The Articles of Association were amended in connection with the exercise of certain investor warrants. On November 4, 2025, the Company registered a share capital increase of nominal DKK 468,750 with the Danish Business Authority, corresponding to an increase in the Company’s share capital to nominal DKK 104,252,689, to reflect the issuance of 1,875,000 ordinary shares in connection with the exercise of certain holders of warrants against cash consideration of USD 101,625 (or approximately DKK 659,109.26 based on the applicable USD-DKK exchange rate on November 4, 2025). The amended Articles of Association are attached hereto as Exhibit 1.1. Exhibits Exhibit No. Description 1.1 Articles of Association SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Evaxion A/S Date: November 18, 2025 By: /s/ Birgitte Rønø Birgitte Rønø Interim Chief Executive Officer EX-1.1 2 exh_11.htm EXHIBIT 1.1 Exhibit 1.1 VEDTÆGTER	 /	ARTICLES OF ASSOCIATION EVAXION A/S CVR-nr. 31762863 1. Selskabets navn og formål 1. Name and object 1.1 Selskabets navn er Evaxion A/S. Selskabet driver tillige virksomhed under binavnene Evaxion Biotech A/S og NovVac A/S. 1.1 The name of the Company is Evaxion A/S. The Company also carries on business under the secondary names Evaxion Biotech A/S and NovVac A/S. 1.2 Selskabets formål er at skabe avanceret software med henblik på udvikling af nye immunterapier og vacciner. 1.2 The objective of the Company is to create advanced software that enables the development of novel immune t